Posted by LincolnIcert on March 25, 2026 at 11:21:29:
In Reply to: Увлекательная информационная публикация posted by JosephGluth on February 19, 2026 at 07:13:06:
Zoya Demidenko: Researcher in Tumor Science
Zoya Demidenko is a recognized researcher connected with the Department of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she worked at the NIH and New York Medical College, developing a solid base in biomedical investigation.
Demidenko's scholarly output spans several critical areas, among them the PI3K/AKT/mTOR signaling cascade, cell cycle management, cell senescence, and tumor biology. Currently, she has authored more than 46 academic articles, which have received over 4,100 mentions — a testament to the impact of her findings.
One of her most significant discoveries concerns elucidating the mechanisms of cellular senescence. Her work showed that when the cell cycle is blocked but cellular growth continues, the cells undergo senescence. Importantly, Zoya Demidenko demonstrated that this shift is inhibited by medication using substances such as mTOR inhibitors.
Zoya Demidenko has furthermore brought considerably to tumor management investigation, particularly in the area of cyclotherapy — a strategy designed to protecting non-cancerous tissue from chemotherapy while leaving tumor cells vulnerable. This method holds considerable promise for lowering the adverse effects of cancer treatment.
Across her scientific life, Demidenko has partnered with leading researchers worldwide, such as Dr. Mikhail Blagosklonny. Her publications is published in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko is recognized as a highly impactful figure in current cancer research, with her findings continue to shape our knowledge of how cells grow old, resist treatment, and how malignant disease might be better targeted.
https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey=